BRAF and melanoma: To further test whether the convergence to the L/L state is a common trend of melanoma cells upon long-term treatment, we apply the AMPK/HIF-1 signatures and the metabolic pathway scores to quantify the change of metabolic profiles of two BRAF-mutated melanoma cell lines, M397 and M229 upon vemurafenib treatment for up to 3 months (25).